No Data
A Potential Challenger For AstraZeneca's Blockbuster Lung Cancer Drug?
TYK MEDICINES-B (02410.HK) plans to hold a Board of Directors meeting on March 27 to approve the annual performance.
Gelonghui reported on March 17 that TYK MEDICINES-B (02410.HK) announced that the Board of Directors meeting will be held on March 27, 2025 (Thursday), to consider and approve the company's and its subsidiaries' annual performance for the year ending December 31, 2024, and its publication, as well as to consider the distribution of a final dividend (if any).
TYK Medicines, Inc Announces Upcoming Board Meeting for Annual Results
TYK MEDICINES-B: DATE OF BOARD MEETING
The first in the field of lung cancer! The domestically produced Innovative Drugs 'head-to-head' defeated the original research drug, yet it is still met with skepticism.
① The TY-9591 by Tongyuankang Pharmacy stood out in head-to-head competition with the "miracle drug for lung cancer" Osimertinib; ② This key phase II clinical trial uses the objective response rate (ORR) as the primary research endpoint, with some opinions suggesting that the level of evidence is a bit weak; ③ Even with solid data, TY-9591 will face fierce market competition in the future.
Key clinical data meet research expectations, TYK MEDICINES-B (02410) demonstrates high value potential.
TYK MEDICINES-B (02410) announced on March 9, 2025, that its independently developed TY-9591 (brand name: Kadasha) demonstrated statistically significant meaning and substantial clinical benefit in a key Phase II clinical trial comparing it to Osimertinib (brand name: Tagrisso) as a first-line treatment for EGFR mutation lung cancer with brain metastasis, according to data from researchers.
